A Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety between CT-P10, Rituxan and MabThera in Patients with Rheumatoid Arthritis
Phase of Trial: Phase III
Latest Information Update: 17 Jun 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Celltrion
- 17 Jun 2017 Results evaluating long term efficacy up-to 48 weeks, presented at the 18th Annual Congress of the European League Against Rheumatism.
- 17 Jun 2017 Results of post hoc analysis (n=332) presented at the 18th Annual Congress of the European League Against Rheumatism.
- 14 Jun 2017 According to a Celltrion media release, data presented at the European League Against Rheumatism (EULAR) congress 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History